

31 January 2023

**Cizzle Biotechnology Holdings Plc**

("Cizzle Biotechnology" or the "Company")

**Total Voting Rights**

Cizzle Biotechnology, the UK based diagnostics developer, makes the following announcement in accordance with Rule 5.6.1 of the Financial Conduct Authority's ("FCA") Disclosure Guidance and Transparency Rules.

As of 31 January 2023, the Company's issued ordinary share capital consists of 347,175,106 ordinary shares of 0.01 pence each, each with one voting right. The Company holds no ordinary shares in Treasury. Therefore, the Company's total number of ordinary shares and voting rights is 347,175,106 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

**Enquiries:**

**Cizzle Biotechnology Holdings plc**  
Allan Syms (Executive Chairman)

**Via IFC Advisory**

**Allenby Capital Limited**  
John Depasquale  
George Payne

**+44(0) 20 33285656**

**Novum Securities Limited**  
Colin Rowbury  
Jon Bellis

**+44(0) 20 7399 9400**

**IFC Advisory Limited**  
Tim Metcalfe  
Florence Chandler

**+44(0) 20 3934 6630**  
**cizzle@investor-focus.co.uk**

**Notes to Editors:**

**About Cizzle Biotechnology**

Cizzle Biotechnology is a spin- out from the University of York that is developing a blood test for the early detection of lung cancer. Its proof-of-concept prototype test is based on the work of Professor Coverley and colleagues to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer. For more information, please see <https://cizzlebiotechnology.com> You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TVREAPFEDFFDEFA